Healthcare Professionals
Please log in for special information and services
New here?
sign up for personal account
DR. Detlef Jakschies Business Development Manager AOP Orphan Germany

"I am very proud to work for AOP Orphan Pharmaceuticals GmbH and lead the German team. The company has been investing for decades in the medicines and medical devices for the treatment of patients with rare diseases, such as myeloproliferative disorders (MPN). Our focus is to help every single patient in Germany."

Facts & Figures  

AOP Orphan is fully dedicated to pharmaceutical and clinical development as well as commercialization of drugs for more than 20 years already.

Our motivation at AOP Orphan is to help patients who suffer from rare diseases. We achieve this cooperating with stakeholders of the German health care system. Partnerships within pharmaceutical and health care industry are crucial for finding and providing solutions for patients, especially in the treatment of orphan diseases. 

Germany occupies a particular position among many countries where AOP Orphan is represented since it was one of the first expansion territory. The company began its development in Germany in 2011 and was transformed into a legal entity in 2018. 

AOP Orphan Germany is a team of around eight employees in the Marketing & Sales, Medical Affairs and Market Access in HematoOncology division. 

 

4mio
people
4 mio affected people
In Europe those diseases that occur in less than 5 per 10,000 residents are defined as rare diseases. More than 4 mio people have been affected with rare diseases in Germany.
HematoOncology 
As a specialist for rare diseases AOP Orphan provides innovative solutions in Germany in the therapeutic area of HematoOncology.
HON
therapeutic area
3
PRODUCTS
3 Innovative Products
AOP Orphan Germany provides three innovative treatments of rare diseases and symptoms.